Bokf Na Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Bokf Na decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,552 shares of the medical research company’s stock after selling 508 shares during the period. Bokf Na’s holdings in Charles River Laboratories International were worth $1,033,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brevan Howard Capital Management LP raised its holdings in shares of Charles River Laboratories International by 90.0% during the fourth quarter. Brevan Howard Capital Management LP now owns 8,008 shares of the medical research company’s stock valued at $1,478,000 after purchasing an additional 3,794 shares during the last quarter. Bridgefront Capital LLC lifted its holdings in shares of Charles River Laboratories International by 52.6% during the 4th quarter. Bridgefront Capital LLC now owns 5,845 shares of the medical research company’s stock valued at $1,079,000 after buying an additional 2,014 shares during the period. Balyasny Asset Management L.P. purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth $1,052,000. Bayesian Capital Management LP purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth $3,316,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Charles River Laboratories International by 13.8% in the fourth quarter. BNP Paribas Financial Markets now owns 90,083 shares of the medical research company’s stock worth $16,629,000 after acquiring an additional 10,912 shares during the period. Institutional investors own 98.91% of the company’s stock.

Insider Activity

In related news, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on CRL. UBS Group reissued a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and upped their target price for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research report on Monday, March 3rd. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and a consensus price target of $176.00.

Charles River Laboratories International Trading Up 3.4 %

Shares of Charles River Laboratories International stock opened at $141.59 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The business has a 50-day moving average price of $138.92 and a 200-day moving average price of $166.78. The firm has a market cap of $6.95 billion, a price-to-earnings ratio of 943.95, a PEG ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.27 EPS. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).